A Randomized Control Trial for Patient Reported Outcomes and Safety in Outpatient Thyroid Lobectomy
Launched by M.D. ANDERSON CANCER CENTER · Oct 10, 2023
Trial Information
Current as of September 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how patients feel about their recovery after a thyroid lobectomy, which is a surgery to remove part of the thyroid gland. The researchers want to compare two different ways of handling recovery: some patients will go home on the same day as their surgery, while others will stay in the hospital overnight or longer. The goal is to understand which option is safer, how patients prefer to recover, and how these choices impact healthcare resources and costs.
To participate, you need to be at least 18 years old and scheduled for your first thyroid lobectomy. The trial welcomes patients who speak English and those who don’t. However, there are some people who cannot join, such as those at high risk of bleeding or with certain health issues that require them to stay in the hospital. If you live more than 50 miles from the hospital or don’t have someone to help you at home after surgery, you also wouldn’t be eligible. If you decide to join, you can expect to be part of a study that aims to improve how recovery is managed and to learn more about what works best for patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients ≥18 years of age
- • 2. Patients undergoing initial partial or complete thyroid lobectomy
- • 3. English and non-English speaking patients are eligible
- Exclusion Criteria:
- • 1. Increased risk of bleeding (e.g., Aspirin, antiplatelet therapy, or anticoagulation that cannot be held 5 days before surgery, baseline thrombocytopenia \<50,000/µL)
- • 2. Pre-existing medical comorbidities or poor performance status (Eastern Cooperative Oncology Group performance status \>2) that would otherwise dictate overnight in-hospital postoperative observation
- • 3. Increased distance of residence from index hospital (\>50 miles) or inability to stay within the targeted area (\<50 miles) postoperatively prohibiting timely return to the index hospital in emergent situations
- • 4. Lives alone or unable to independently perform Activities of Daily Living and no available caregiver in the immediate postoperative period (POD 0-3)
- • 5. Pregnant women will not be included in this study
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Paul Graham, M D
Principal Investigator
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported